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PURPOSE. To investigate the effects of paclitaxel associated with lipid nanoemulsions (LDE-
PTX) on postoperative scarring in rabbits undergoing trabeculectomy.
METHODS. Thirty-four rabbits that underwent trabeculectomy were allocated to four groups:
LDE-PTX/SC (n ¼ 9), treated with LDE-PTX (1.5 mg, intraoperative subconjunctival
injection); LDE-PTX/IV (n ¼ 9), treated with LDE-PTX (4 mg/kg per day intravenously) at
the end of the surgery and once per week for 3 weeks; MMC (n ¼ 9), treated with
intraoperative 0.4 mg/mL mitomycin-C for 3 minutes; and control group (CTL, n ¼ 7),
without treatment. Bleb characteristics and IOP were evaluated over 4 weeks. Animals were
killed on day 28. Histologic analyses were performed to assess the amount of scarring and
toxicity to the conjunctiva and ciliary body.
RESULTS. Groups were similar with respect to IOP and anterior chamber depth during the 28-
day observation period. The LDE-PTX/SC, LDE-PTX/IV, and MMC groups showed greater bleb
height than CTL on days 14 and 21 (P < 0.001). The LDE-PTX/SC, LDE-PTX/IV, and MMC
groups showed longer bleb survival time than CTL (P < 0.001). The LDE-PTX/SC, LDE-PTX/IV,
and MMC groups were equally effective in reducing fibrosis (P < 0.001), number of blood
vessels (P < 0.001), and chronic inflammatory cells (P < 0.01) at the surgical site. However,
LDE-PTX/SC and LDE-PTX/IV treatments had lower conjunctival (P < 0.001) and ciliary body
toxicity (P < 0.01), compared with MMC.
CONCLUSIONS. The LDE-PTX/SC was effective in reducing the scarring process following
trabeculectomy to the same extent as MMC, but with considerably less toxicity to the
conjunctiva and ciliary body. The LDE-PTX/IV was somewhat less effective than LDE-PTX/SC
or MMC, but could have potential as a postoperative adjuvant treatment. Therefore, the LDE-
PTX preparation in both administration routes may offer promising options for wound-healing
modulation in the surgical treatment of glaucoma.
Keywords: trabeculectomy, fibrosis prevention and control, wound-healing drug effects, drug
carriers, nanoemulsion therapeutic use, solid lipid particles
Trabeculectomy was introduced by Cairns
1 in 1968 and is
still the gold standard surgical treatment of glaucoma. The
long-term success of this intervention is, however, limited by
the closure of the sclerostomy resulting from excessive
subconjunctival scarring,2 which is considered the major cause
of trabeculectomy failure. Fibroblastic proliferation, scarring of
the trabeculectomy flap, subconjunctival fibrosis, and remod-
eling of collagen with contraction of tissue in and around the
bleb site are the usual postoperative histopathological features
that ultimately lead to the sclerostomy closure.3,4 Subconjunc-
tival antifibrotics, such as mitomycin-C (MMC) and 5-fluoroura-
cil (5-FU), have been used aiming to reduce the formation of
scar tissue, by inhibiting fibroblast proliferation, and interfering
with many steps of the healing cascade.2,5–7 Mitomycin-C is
more effective compared with 5-FU,2 and it is currently used in
more than 85% of the trabeculectomies.8 However, severe
adverse effects and complications, such as bleb leaks, hypotony
and infection may follow the use of MMC.2,9,10 Thus, the
development of alternative therapeutic strategies based on
more effective and safer properties are mandatory to warrant a
better prognosis after trabeculectomy.
In this regard, paclitaxel (PTX), an anticancer agent
belonging to the taxane class, has been shown to enhance
the success of trabeculectomy11–14 due to its capacity of
inhibiting the fibroblast migration and scar contraction,15
similar to MMC.14,16 However, PTX therapeutic efficacy is
limited by the pharmacological instability induced by its
physicochemical properties, such as hydrophobicity.13,14 Lack
of a satisfactory carrier for paclitaxel solubilization is a major
drawback for the use of this agent as an adjuvant therapy for
trabeculectomy. Some carriers, such as polyanhydride disks12
and Carbopol 980 hydrogel,16 have been attempted to achieve
greater stability of PTX for subconjunctival use. However, none
of those PTX formulations was adequate to introduce PTX as a
valid alternative as antifibrotic agent. Moreover, the carrier used
in commercial PTX formulation for intravenous cancer treat-
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ment, Cremophor EL, bears intolerable side effects for
ophthalmological use, such as hypersensitive reactions.17
As previously reported, after intravenous injection, nonpro-
tein lipid nanoparticles termed LDE, that resemble the lipid
structure of low-density lipoprotein (LDL), the lipoprotein that
contains most of cholesterol in the plasma, can bind to the LDL
receptors and concentrate associated drugs in malignant
tumors18–20 or in inflamed tissues as in atherosclerosis,21,22
rheumatic disease,23 or grafted organs.24 This has been shown
not only in animal models of disease,25,26 but also in patients
with either solid18,19 or hematologic tumors.20,27 In both
experimental studies and clinical trials enrolling patients with
cancer, PTX and other antineoplastic agents had their toxicity
drastically decreased by the association to LDE, without
affecting their pharmacological action.19,20,25–27
Overexpression of LDL receptors is the mechanism that
allows the concentration of PTX associated to LDE in the
targeted tissues.19 The need for cholesterol and other lipids for
building new membranes during accelerated mitosis rates
determines the receptor overexpression in neoplastic and
inflammatory tissues.19,22,23 In fact, LDL receptors are also
overexpressed in the activated human tenon fibroblasts,28
which justifies the use of LDE as a PTX carrier for
subconjunctival antiscarring therapy.
This study was designed to test the efficacy and safety of
LDE-PTX as an antiscarring agent in rabbits undergoing
trabeculectomy. We hypothesized that intraoperative LDE-
PTX can be as efficacious, but less toxic, than MMC. Moreover,
because systemic LDE-PTX has been shown to be safe for
human cancer chemotherapy, we also decided to investigate
the intravenous use of LDE-PTX as a possible novel approach in
filtration surgery.
METHODS
Animals
Thirty-four male New Zealand White rabbits (provided by USP
Medical School Animal Care Unit, Sa˜o Paulo, Brazil) weighing
3.5 6 0.4 kg were housed in individual cages in a temperature-
controlled room on a 12-hour light/dark cycle; animals were
fed ad libitum during the experimental period. All animals
underwent trabeculectomy, performed under anesthesia with
intramuscular injection of ketamine (50 mg/kg) and xylazine
(23 mg/kg). Before the surgical procedure, topical anesthetic
eye drop proxymetacaine HCl 0.5% (Anestalcon; Alcon, Sa˜o
Paulo, Brazil) was applied. The rabbits were allocated to four
groups, according to the antiscarring treatment:
1. MMC (n ¼ 9): treated with MMC 0.4 mg/mL29–32
administered with a sponge (Merocel PVA, Beaver-
Visitec, Waltham, MA, USA), placed between the scleral
flap and the conjunctiva-Tenon layer. After 3 minutes,
the sponge was removed and the site was irrigated
thoroughly with balanced saline solution.
2. LDE-PTX/SC (n ¼ 9): treated with a single subconjunc-
tival injection of LDE-PTX (1.5 mg in 300 lL volume) at
the upper cul de sac, after the conjunctival suture. The
choice of the 1.5-mg dose was determined by the
volume (300 lL) that could regularly be injected into the
superior subconjunctival space, without a noticeable
leakage out of the conjunctival hole.33,34
3. LDE-PTX/IV (n ¼ 9): treated with intravenous injection
of LDE-PTX at the 4 mg/kg PTX, used in our previous
studies,22 at the end of the surgery and three subsequent
weekly injections.
4. CTL (n¼ 7): control group, not treated.
The study was carried out in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and was approved by the Medical Experimental
Research Ethics Committee of the School of Medicine of the
University of Sa˜o Paulo (no. 379/13).
Trabeculectomy Procedure and Treatment
Regimen
The surgical procedure was performed in all animals by a
single surgeon (MLO). A superior 8-0 silk corneal traction
suture was placed to allow for infraduction of the globe. After a
superior limbal peritomy, a partial-thickness scleral flap (3.03
3.5 mm) was created, starting 2.5 mm behind the limbus and
continuing until the blade was just visible in the anterior
corneal stroma. The anterior chamber was entered using a 45-
degree blade. A fragment of tissue containing the inner sclera,
trabeculum, and peripheral cornea measuring approximately 2
3 2 mm was excised. A peripheral iridectomy was then
performed and the anterior chamber was filled with balanced
salt solution. The scleral flap and the conjunctiva were closed
with 10-0 nylon sutures. Topical antibiotic with steroid drops
and ointment (ciprofloxacin þ dexamethasone) were used,
once a day, until animals were killed.
After 4 weeks, animals underwent euthanasia by overdose
sodium pentobarbital intravenous injection. Right eyes were
then enucleated to prepare for histopathologic examination by
conventional optical microscopy.
Clinical Evaluation
On the day of the surgery and on days 1, 3, 7, 14, 21, and 28
after the surgery, all animals were examined to measure IOP
and evaluate the bleb characteristics. The IOP was measured at
approximately 9 AM with an applanation tonometer (Tono-Pen
Avia; Reichert, Inc., Depew, NY, USA), under topical anesthesia
with proxymetacaine HCl 0.5%. The average of five readings
was used for the analysis.
A masked observer classified the anterior chamber depth
and bleb height. The anterior chamber depth was graded as
deep, shallow, or flat; bleb height was graded as high, elevated,
shallow, or flat.35 Bleb survival was taken as the primary
efficacy endpoint. Bleb failure was defined when a flat, scarred,
vascularized bleb was observed in association with a deep
anterior chamber.
Preparation of LDE With Associated PTX Oleate
The preparation of LDE-PTX oleate was made by high-pressure
homogenization from a pre-emulsion obtained by ultrasonic
irradiation until complete drug dissolution, according to the
methods described previously.22,25 After the homogenization
cycles, the formed nanoemulsion was centrifuged and the
nanoemulsion sterilized by passage through a 0.22-lm pore
polycarbonate filter (Millipore, Billerica, MA, USA) and kept at 48C
until it was used. The final concentration of PTX oleate
incorporated to LDE was confirmed by HPLC (Shimadzu,
Columbia, MD, USA) and, as determined by this approach, the
yield of association of PTX oleate to LDE was more than 95% and
was not significantly changed by the passage through the 0.22-lm
pore filter. As measured by laser scattering technique (Zetasizer
Nano ZS90; Malvern, Worcester, UK), the average nanoemulsion
particle diameter was 64 nm, with a polydispersity index of 0.162.
Histopathologic Study
Eyes were fixed in formalin for 24 hours and embedded in
paraffin; 5-lm sections of the surgical sites were stained with
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hematoxylin-eosin and with Masson Trichrome. Histological
evaluations were conducted by an experienced pathologist,
who was masked for the groups.
For assessment of scar formation at the subconjunctival
space, the following parameters were evaluated: fibroblast
count, fibrosis, collagen organization, collagen density, stromal
edema, density of blood vessels, and number of mononuclear
cells.
Fibroblasts were graded according to Butler et al.36 as
follows: absent, without fibroblasts in the tissue; low count,
when involving less than 50% of tissue; moderate count, when
involving between 50% and 80% of tissue; and high count,
when involving ‡80% of the tissue. Stromal edema was scored
according to the same scale36 as follows: absent, without
edema in the tissue; mild, when involving less than 50% of
tissue; moderate, when involving between 50% and 80% of
tissue; and intense, when involving ‡80% of the tissue. The
fibrosis grading scale, according to Koz et al.,16 was as follows:
negative, if less than 10% of the field was constituted by
fibrous tissue; mild, if between 10% and 25%; moderate, if
between 26% and 75%; and severe, if more than 75%.
To evaluate collagen organization, the scoring system
described by Ekinci et al.37 was used: no stromal disorgani-
zation, with parallel mature collagen fibers; weak stromal
disorganization, with long and discrete collagen fibers;
moderate stromal disorganization, with shortened and focal
perpendicular sequence of collagen fibers; and strong stromal
disorganization, with collagen fibers shortened and ponting
in all directions. Subconjunctival collagen density was graded
according to Perkins et al.38: no alteration, with no stain;
minimal alterations, with light blue stain; mild alterations,
with mild blue stain; moderate alterations, with fairly blue
stain; and severe alterations, with densely blue stain.
Density of blood vessels in the subconjunctival tissue was
graded according to Okuda et al.,39 with slight modifications:
no blood vessel per image; 1 to 5 blood vessels per image, and
6 to 20 blood vessels per image. Mononuclear cells were
counted at 10 high-power fields, and the average number of
cells in these zones was analyzed.
For the assessment of conjunctival toxicity, we used the
grading system described by Polak et al.,40 slightly modified by
Ekinci et al.37: no histologic alteration, normal conjunctival
tissue and no inflammation; minimal histologic alterations,
demonstrating thickening of the conjunctiva but preservation
of the conjunctival epithelium; mild histologic alterations,
demonstrating thickening of the conjunctiva, conjunctival
epithelium preserved, and mild inflammatory cell infiltration;
moderate histologic alterations, demonstrating thickening of
the conjunctiva, conjunctival epithelium preserved, mild
inflammatory cell infiltration, and loss of collagen fibril
organization; severe histologic alterations, with loss of
conjunctival epithelium, total disorganization, and necrosis of
the underlying scleral stroma. Goblet cells were counted at 10
high-power fields, and the average number of these cells was
analyzed.
For the assessment of ciliary body toxicity, we evaluated
three parameters based on the grading system published by
Ekinci et al.37: ciliary epithelium height, vascular congestion
(distension of vascular lumens by erythrocytes), and edema
(distension of the stromal collagen fibers) in the ciliary body.
Alterations in ciliary epithelium height were scored as
minimal decrease, mild decrease, moderate decrease, and
severe decrease; whereas the intensity of edema and conges-
tion were scored as absent, minimal, mild, moderate, and
severe.
Statistical Analysis
Statistical analysis was performed using SPSS 20.0 statistical
software (IBM SPSS Statistics, IBM Corporation, Chicago, IL,
USA). Survival analysis of the surgery was performed using the
Kaplan-Meier curve and the log rank test. The quantitative
parameters were analyzed using the Kruskal-Wallis test,
followed by Bonferroni correction for multiple analyses. All
the semiquantitative parameters were analyzed using the
Kruskal-Wallis test, followed by the test for multiple compar-
isons of Dunn. For all the analyses, P < 0.05 was considered
statistically significant.
RESULTS
Clinical Findings
No ocular complications, such as conjunctival redness,
chemosis, or discharge, were observed. Body weight and
hematologic profiles were not different among the treatment
groups and between the day when surgery was performed and
the euthanasia day (data not shown).
Bleb Survival
In all animals, trabeculectomies were successful in achieving
filtration, leading to flattening of the anterior chamber and
high-filtering blebs, as observed on the first day after the
procedure. Flattening of the anterior chamber was maintained
during the first 3 days in all groups, with deepening in
gradation over time, until day 28, when the anterior chamber
was deep in all groups.
In respect to the bleb height, as shown in Figure 1, all study
groups showed high blebs 1 day after the surgery. During the
first week, blebs were classified as elevated in all groups. By
FIGURE 1. External appearance of filtering blebs of eyes treated with
LDE-PTX or MMC after trabeculectomy. At the first week, all the groups
exhibited elevated, diffuse, fleshy-looking blebs. Over time, these blebs
became more focal (less diffuse) in appearance (outline), until their
failure (flat, scarred, and vascularized bleb), earlier (in day 14) in the
CTL group. The animals shown are representative of the time course of
healing for all groups.
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day 14, LDE-PTX/IV and CTL groups showed shallow or flat
scores in most animals, although LDE-PTX/IV showed signifi-
cantly better scores than CTL (P < 0.01). In contrast, LDE-PTX/
SC and MMC eyes still showed high and elevated scores on day
14, but this condition subsided by day 21, when most animals
of these groups showed flat or shallow blebs, although still
significantly better than CTL (P < 0.01). By day 28, most
animals of all three treated groups and CTL had equally attained
flat blebs.
Survival curves of the blebs are shown in Figure 2. The
survival times of all treatment groups were significantly longer
compared with CTL (P < 0.001). The median survival times
were 14, 21, 28, and 28 days for the CTL, LDE-PTX/IV, LDE-
PTX/SC, and MMC groups, respectively. There were no
significant differences in survival times among the three
treatment groups.
Intraocular Pressure
Figure 3 illustrates the IOP variation after trabeculectomy in all
groups. The IOP significantly decreased on the first day after
the surgery (P < 0.001), and gradually increased over time in
all groups. There were no significant differences regarding IOP
control among the four groups over the entire study period.
Histopathologic Features
Histologic analysis of the eyes, performed at the center of the
sclerostomy site, as indicated by the location of iridectomy,
showed several significant differences among the study groups
(Table 1). The three treated groups showed lower number of
fibroblasts, involving less than 50% of the tissue, compared
with the CTL group (P < 0.001 versus MMC, P < 0.01 versus
LDE-PTX/SC and LDE-PTX/IV). Similarly, the treated groups
showed mild fibrosis, whereas the CTL group showed
moderate or severe fibrosis (P < 0.001 versus MMC and LDE-
PTX/SC; P < 0.01 versus LDE-PTX/IV). There were no
differences in these parameters among the LDE-PTX/SC, LDE-
PTX/IV, and MMC groups (Table 1).
Compared with CTL, in the three treated groups collagen
fibers were more disorganized (LDE-PTX/SC, P < 0.01; MMC, P
< 0.001) or tended to be more disorganized (LDE-PTX/IV, P¼
0.051), which implies reduced fibrosis. The LDE-PTX/SC and
MMC collagen fibers were equally disorganized, but LDE-PTX/
IV showed less fiber disorganization than the MMC group (P <
0.05) (Table 1; Fig. 4).
As shown in Table 1, LDE-PTX/SC, LDE-PTX/IV, and MMC
showed minimal or mild changes in collagen density, compared
with CTL, where severe alterations occurred (P < 0.01, P <
0.05, P < 0.001, respectively). In the LDE-PTX/SC and MMC
groups, the collagen density was similar, but LDE-PTX/IV
showed greater collagen density than MMC (P < 0.05). Figure 4
shows the presence of immature fibrosis in the treated groups,
in contrast to well-organized and dense fibrosis that appears in
the CTL group.
As shown in Table 1, the density of blood vessels in the
subconjunctival tissue was significantly lower in the treated
groups than in the CTL group (P < 0.001 versus LDE-PTX/SC
and MMC, P < 0.01 versus LDE-PTX/IV). Furthermore, there
was more stromal edema in the subconjunctival space of
treated eyes than in the CTL group (P < 0.01 versus LDE-PTX/
SC and LDE-PTX/IV and P < 0.05 versus MMC) (Table 1).
Moreover, the number of mononuclear cells was diminished by
60% in the treated groups, compared with CTL (P < 0.01
versus MMC and LDE-PTX/IV; P < 0.001 versus LDE-PTX/SC)
(Table 1). This latter finding suggests that the chronic
inflammation that follows trabeculectomy was attenuated by
all the three treatments.
Regarding conjunctival toxicity (Table 2; Fig. 5), the
treatment with either LDE-PTX/SC or LDE-PTX/IV did no harm
to the conjunctival tissue, which remained similar to CTL. In
contrast, MMC treatment elicited moderate to severe histologic
alterations in the conjunctival structure, such as loss of
conjunctival epithelium, loss of collagen fibril organization,
and increased inflammatory cell infiltration, as compared with
CTL (P < 0.01). The MMC treatment resulted in a pronounced,
8-fold reduction in the number of goblet cells (P < 0.001).
Goblet cells were also reduced in the LDE-PTX/SC group
compared with CTL (P < 0.01).
Figure 5 and Table 3 show the analysis of ciliary body
toxicity. The MMC treatment produced a pronounced decrease
in the epithelium height, a change in the cellular shape, from
cubical to columnar, with increased congestion and edema (P
< 0.01 versus CTL). In contrast, the ciliary body was not
changed by either LDE-PTX/SC or LDE-PTX/IV treatments, as
compared with the CTL group.
DISCUSSION
Rabbit trabeculectomy is the chief experimental model for this
procedure in the literature.41 Interestingly, the wound-healing
FIGURE 2. Kaplan-Meier bleb survival plot of eyes treated with LDE-
PTX or MMC after trabeculectomy. Filtering blebs in the CTL group
almost failed within 2 weeks. Treatment with LDE-PTX/SC and LDE-
PTX/IV markedly increased the bleb survival period. In the MMC
group, the bleb survived nearly 4 weeks as well in LDE-PTX/SC group.
A Kaplan-Meier analysis showed a significant difference in the survival
distributions among the four groups (log rank ¼ 20.6; P < 0.001).
FIGURE 3. Intraocular pressure changes over time of eyes treated with
LDE-PTX or MMC after trabeculectomy. Postoperative IOP was
significantly lower than baseline in all groups (P < 0.001). The gradual
increase of IOP during the study period was not significantly different
among all groups.
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response at the surgical site in the rabbit is more aggressive
than in human subjects.42,43 In some studies, devices such as
needle fragments connecting the anterior chamber to the
subconjunctival space are used, aiming to extend the patency
FIGURE 4. Collagen organization and collagen density (A–D) and
stromal edema (E–H) in the subconjunctival space in CTL (A, E), MMC
(B, F), LDE-PTX/SC (C, G), and LDE-PTX/IV (D, H) groups. (A–D) Note
the lighter blue staining indicating the disorganized neoformed collagen
fibers and less density of the tissue in the three treatment groups (B, C,
D). (E–H) Note the cystic spaces throughout the subconjunctival space,
demonstrating filtration through the loose collagen fibers in the all
treated groups (F, G, H), compared with CTL (E), which shows minimal
edema, due to more compact collagen fibers. (A–D) Hematoxylin-eosin
stain. (E–H), Masson Trichrome stain. Magnification:340.
TABLE 1. Histopathologic Alterations in the Subconjunctival Tissue of Eyes Treated With LDE-PTX or MMC After Trabeculectomy
CTL MMC LDE-PTX/SC LDE-PTX/IV P
Fibroblasts *** ** ** <0.001
Absent 0 (0) 0 (0) 0 (0) 0 (0)
Low count 0 (0) 9 (100) 8 (88.9) 7 (77.8)
Moderate count 4 (57.1) 0 (0) 1 (11.1) 2 (22.2)
High count 3 (42.9) 0 (0) 0 (0) 0 (0)
Fibrosis *** *** ** <0.001
Negative 0 (0) 2 (22.2) 0 (0) 0 (0)
Mild 0 (0) 6 (66.7) 9 (100) 6 (66.7)
Moderate 3 (42.9) 1 (11.1) 0 (0) 3 (33.3)
Severe 4 (57.1) 0 (0) 0 (0) 0 (0)
Collagen fiber organization *** ** † <0.001
No stromal disorganization 5 (71.4) 0 (0) 0 (0) 0 (0)
Weak stromal disorganization 1 (14.3) 0 (0) 0 (0) 2 (22.2)
Moderate stromal disorganization 1 (14.3) 4 (44.4) 6 (66.7) 7 (77.8)
Strong stromal disorganization 0 (0) 5 (55.6) 3 (33.3) 0 (0)
Collagen density *** ** * † <0.001
No alteration 0 (0) 0 (0) 0 (0) 0 (0)
Minimal alterations 0 (0) 9 (100) 5 (55.6) 3 (33.3)
Mild alterations 0 (0) 0 (0) 4 (44.4) 4 (44.4)
Moderate alterations 2 (28.6) 0 (0) 0 (0) 2 (22.2)
Severe alterations 5 (71.4) 0 (0) 0 (0) 0 (0)
Density of blood vessels *** *** ** <0.001
No blood vessels 0 (0) 0 (0) 0 (0) 0 (0)
1–5 blood vessels 0 (0) 9 (100) 9 (100) 8 (88.9)
6–20 blood vessels 7 (100) 0 (0) 0 (0) 1 (11.1)
Stromal edema * ** ** 0.001
Absent 5 (71.4) 1 (11.1) 0 (0) 1 (11.1)
Mild 2 (28.6) 7 (77.8) 7 (77.8) 5 (55.6)
Moderate 0 (0) 0 (0) 2 (22.2) 2 (22.2)
Intense 0 (0) 1 (11.1) 0 (0) 1 (11.1)
Number of mononuclear cells ** *** ** 0.001
9.8 6 1.8 4.0 6 1.4 3.7 6 1.9 4.3 6 1.2
Values are expressed as n (%) or mean 6 SD. * P < 0.05, ** P < 0.01, *** P < 0.001 versus CTL; † P < 0.05 versus MMC, by Kruskal-Wallis
followed by Dunn posttest or followed by Bonferroni posttest.
FIGURE 5. Conjunctival (A–D) and ciliary body (E–H) toxicity in CTL
(A, E), MMC (B, F), LDE-PTX/SC (C, G), and LDE-PTX/IV (D, H) groups.
(A–D) Note the conjunctival epithelium preserved, with minimal
thickening of conjunctiva, and normal range count of healthy goblet
cells in the LDE-PTX/SC (C), LDE-PTX/IV (D), and CTL (A)
(arrowhead) groups. The MMC group (B) showed loss of goblet cells
and moderate to severe alterations to the conjunctiva structure, such as
loss of conjunctival epithelium, collagen fibril disorganization, and
thinning of the underlying substantia propria (black arrows). (E–H)
Note the normal ciliary body appearance, with preservation of ciliary
body epithelium height and minimal congestion and edema in the LDE-
PTX/SC (G), LDE-PX/IV (H), and CTL (E) groups, in contrast to the
decrease of the epithelial height and disruption of the bilayered ciliary
epithelium cells (black arrows), associated with severe congestion and
edema (arrowhead) in the MMC (F) group. (A–H) Hematoxylin-eosin
stain. Magnification:340.
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of the surgically created fistula.44 However, this experimental
technique creates an artificial fistula, with its own particular
scarring process.
This study showed that LDE-PTX/SC was as effective as
MMC in preventing scarring after trabeculectomy. This
statement is supported by bleb survival data and, most
importantly, by the histological findings. Both LDE-PTX/SC
and MMC were equally effective in reducing the fibrosis and
chronic inflammatory cell counts (Table 1). Compared with
the control group, microscopic appearance of the surgical site
was fairly different in the animals treated with either LDE-PTX/
SC or MMC. The changes were consistent with a clear
antifibrotic pharmacological action of both preparations, with
less-dense and disorganized collagen tissue and with reduced
number of fibroblasts and mononuclear cells. Loose, less-
organized collagen permits the permeation of aqueous from
the anterior chamber, which accounts for the greater stromal
edema that occurred in the animals treated with LDE-PTX/SC
or with MMC.
Although LDE-PTX/SC showed antiscarring pharmacologi-
cal action similar to MMC, the toxicity of the preparation to the
conjunctiva and ciliary body was clearly smaller than that
elicited by MMC treatment. The MMC group showed atrophic
changes in the conjunctival epithelium and decreased count of
goblet cells, in most of the animals, which did not occur in the
LDE-PTX/SC group. The cell number was nonetheless within
the minimal normal figure, which is approximately seven cells
per high-powered field.45 Conjunctival epithelium atrophy
leads to thin-walled blebs, a commonly undesirable effect of
MMC-treated eyes.2,46 On the other hand, the depletion of
goblet cells may contribute to the exacerbation of dry-eye
symptoms in patients after trabeculectomy, and also to the
weakening of the conjunctival structure, facilitating bleb
leakages.47,48 In this setting, the finding that LDE-PTX/SC but
not MMC may preserve both the conjunctival epithelium and
the goblet cells is an important advantage of this novel
approach. Furthermore, with regard to ciliary body toxicity,
epithelium height reduction, as well as the congestion and
edema of the ciliary body were significantly more intense in
the MMC group than in the LDE-PTX/SC group. All the several
toxic effects of MMC observed in this study have been
previously reported in the literature.49–52
In this study, the possibility of using LDE-PTX/IV was also
explored, as the systemic use of this preparation was proven
devoid of significant toxicities not only in experimental studies
with animals but also in clinical trials enrolling patients with
cancer.19,20,27 Our findings suggest that LDE-PTX/IV antiscar-
ring action is slightly inferior to those of MMC and LDE-PTX/
TABLE 2. Toxic Conjunctival Changes at the Filtration Site of Eyes Treated With LDE-PTX or MMC After Trabeculectomy
CTL MMC LDE-PTX/SC LDE-PTX/IV P
Conjunctival toxicity ** ††† ††† <0.001
No alteration 0 (0) 0 (0) 0 (0) 0 (0)
Minimal alterations 3 (42.9) 0 (0) 7 (77.8) 8 (88.9)
Mild alterations 4 (57.1) 0 (0) 2 (22.2) 1 (11.1)
Moderate alterations 0 (0) 8 (88.9) 0 (0) 0 (0)
Severe alterations 0 (0) 1 (11.1) 0 (0) 0 (0)
Number of goblet cells *** ** †† ††† <0.001
20.9 6 9.7 2.5 6 1.6 11.6 6 3.4 16.4 6 3.4
Values are expressed as n (%) or mean 6 SD. ** P < 0.01, *** P < 0.001 versus CTL; †† P < 0.01, ††† P < 0.001 versus MMC, by Kruskal-Wallis
followed by Dunn posttest or followed by Bonferroni posttest.
TABLE 3. Toxic Ciliary Body Changes of Eyes Treated With LDE-PTX or MMC After Trabeculectomy
CTL MMC LDE-PTX/SC LDE-PTX/IV P
Ciliary epithelium height *** †† ††† <0.001
Minimal decrease 7 (100) 0 (0) 5 (55.6) 8 (88.9)
Mild decrease 0 (0) 0 (0) 4 (44.4) 1 (11.1)
Moderate decrease 0 (0) 5 (55.6) 0 (0) 0 (0)
Severe decrease 0 (0) 4 (44.4) 0 (0) 0 (0)
Congestion *** ††† †† <0.001
Absent 0 (0) 0 (0) 0 (0) 0 (0)
Minimal 6 (85.7) 0 (0) 2 (22.2) 4 (44.4)
Mild 1 (14.3) 1 (11.1) 7 (77.8) 3 (33.3)
Moderate 0 (0) 3 (33.3) 0 (0) 2 (22.2)
Severe 0 (0) 5 (55.6) 0 (0) 0 (0)
Edema ** †† †† <0.001
Absent 5 (71.4) 1 (11.1) 8 (88.9) 9 (100)
Minimal 2 (28.6) 5 (55.6) 1 (11.1) 0 (0)
Mild 0 (0) 3 (33.3) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0)
Values are expressed as n (%). ** P < 0.01, *** P < 0.001 versus CTL; †† P < 0.01, ††† P < 0.001 versus MMC, by Kruskal-Wallis followed by Dunn
posttest.
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SC. The systemic administration of LDE-PTX was able to
decrease the formation of fibrous tissue in the subconjunctival
space and to increase the bleb survival. However, in only two
of the parameters we measured, namely the degree of collagen
organization and collagen density parameters, LDE-PTX/IV
showed inferiority to MMC.
As a limitation of the study, the experiments were
performed only in male animals. Gender can play a role in
wound healing due to the different effects of androgens and
estrogens on the various phases of the healing process.53
Apparently, estrogen administration accelerates wound repair,
whereas androgens have a negative effect.54–56 Thus, experi-
ments in female rabbits should be performed to validate the
effects of LDE-PTX in female animals.
Regarding the toxicity to the eye, LDE-PTX/IV harmful
effects to conjunctiva and to ciliary body were minimal, similar
to LDE-PTX/SC and pronouncedly smaller than those elicited
by MMC use. Those findings indicate that LDE-PTX/IV may be
used as an adjuvant pharmacological tool in the wound-healing
modulation in trabeculectomy. However, an important issue
that arises from the use of IV LDE-PTX refers to the potential
systemic toxicity, especially myelotoxicity. In this study, no
hematological toxicity was observed in the rabbits (data not
shown).
The current status of glaucoma surgery requires new
approaches57,58 to prolong the duration of the filtering
patency by improving the efficacy and decreasing the toxicity
of antifibrotic agents. The results of this study suggest that
LDE-PTX may become an alternative not only for intraoper-
ative but eventually for subsequent maintenance of the
surgical fistula.
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